Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.53 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.52 |
| ▸ | GRM5 | P41594 | 3/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.44 |
| ▸ | COMT | P21964 | 1/20 | 0.43 |
| ▸ | PRKCI | P41743 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7921223 | 0.84 | GRM5 (0.53) | ASIC3GRM5 | |
| SCHEMBL20625047 | 0.84 | GRM5 (0.49) | ASIC3GRM5PIK3CDPIK3CAMTOR | |
| SCHEMBL4309708 | 0.84 | CYP17A1 (0.53) | ASIC3GRM5 | |
| SCHEMBL3797658 | 0.84 | CYP1A1 (0.56) | ASIC3GRM5APPCOMTKCNH2 | |
| SCHEMBL9928719 | 0.84 | NOTUM (0.61) | NOTUMGRM5APPPIK3CDPIK3CA | |
| SCHEMBL9610050 | 0.84 | APP (0.55) | NOTUMGRM5APPPIK3CDPIK3CA | |
| SCHEMBL4410475 | 0.83 | GRM5 (0.52) | GRM5APPPIK3CDPIK3CAMTOR | |
| SCHEMBL2925968 | 0.83 | APP (0.67) | NOTUMGRM5APPPIK3CDPIK3CA | |
| SCHEMBL4311440 | 0.81 | GRM5 (0.51) | ASIC3GRM5PIK3CAPDK1KCNH2 | |
| SCHEMBL16108938 | 0.81 | CYP2A6 (0.54) | ASIC3GRM5COMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042908-A1 | AMINO-5-(6-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR BETA-SECRETASE MODULATION | WYETH (US) | 2009-02-12 | — | — | US | disclosed |
| US-20090042908-A1 | AMINO-5-(6-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR BETA-SECRETASE MODULATION | WYETH (US) | 2009-02-12 | — | — | US | disclosed |
| US-7452885-B2 | Amino-5-(6-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation | WYETH (US) | 2008-11-18 | — | — | US | disclosed |
| US-7452885-B2 | Amino-5-(6-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation | WYETH (US) | 2008-11-18 | — | — | US | disclosed |
| EP-1896448-A1 | AMINO-5-(6-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR ß-SECRETASE MODULATION | Wyeth (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007005404-A1 | AMINO-5-(6-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR ß-SECRETASE MODULATION | WYETH (US) | 2007-01-11 | — | — | WO | disclosed |
| WO-2007005404-A1 | AMINO-5-(6-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR ß-SECRETASE MODULATION | WYETH (US) | 2007-01-11 | — | — | WO | disclosed |
| US-20070004730-A1 | Amino-5-(6-membered)heteroarylimidazolone compounds and the use thereof for beta-secretase modulation | WYETH (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070004730-A1 | Amino-5-(6-membered)heteroarylimidazolone compounds and the use thereof for beta-secretase modulation | WYETH (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004730-A1 | Amino-5-(6-membered)heteroarylimidazolone compounds and the use thereof for beta-secretase modulation | BACE1, BACE2, APP | ASIC3 4086/4885NOTUM 977/4885GRM5 196/4885 |
| US-20090042908-A1 | AMINO-5-(6-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR BETA-SECRETASE MODULATION | BACE1, BACE2, APP | ASIC3 4086/4885NOTUM 977/4885GRM5 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.